7 results match your criteria: "From the Kirby Institute.[Affiliation]"
Article Synopsis
- * It found a significant decrease in "frequent comprehensive testing" among HIV-negative GBM using PrEP, dropping from 71.7% in 2017 to 58.6% in 2021, with similar declines in non-PrEP users and HIV-positive participants.
- * The research suggests many GBM are not adhering to Australian STI testing guidelines of quarterly testing, prompting a call for further evaluation of the guidelines' relevance and necessity.
Background: Gay and bisexual men (GBM) who use HIV preexposure prophylaxis (HIV-PrEP) have high rates of bacterial sexually transmitted infections (STIs). The use of daily antibiotics as STI preexposure prophylaxis (STI-PrEP) may be appealing to GBM who are using or have previously used HIV-PrEP (HIV-PrEP-experienced) for the prevention of bacterial STIs.
Methods: We examined willingness to use daily STI-PrEP among a cross-sectional sample of HIV-PrEP-experienced GBM in Australia who participated in an observational online cohort study from August 2018 to March 2020.
People with Hepatitis C Who Inject Drugs - Underserved, Not Undeserving.
N Engl J Med
August 2020
From the Kirby Institute, UNSW Sydney, and St. Vincent's Hospital - both in Sydney (G.J.D.); and Philadelphia FIGHT Community Health Centers and the Perelman School of Medicine, University of Pennsylvania - both in Philadelphia (S.T.).
Biological and Behavioral Factors Associated With Positive Chlamydia Retests.
Sex Transm Dis
July 2017
From the *Kirby Institute, UNSW Australia, Sydney; †Murdoch Childrens Research Institute; ‡Department of Microbiology and Infectious Diseases, The Royal Women's Hospital; §Department of Obstetrics and Gynaecology, University of Melbourne; ¶Melbourne Sexual Health Centre; ∥Central Clinical School, Monash University, Melbourne; **Sydney Sexual Health Centre; ††School of Public Health and Community Medicine, UNSW Australia; ‡‡Serology and Virology Division, (SAViD) SEALS Microbiology, Prince of Wales Hospital; §§SOMS and BABS, UNSW Australia, Sydney; ¶¶VCS Pathology; and ∥∥Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.
Background: Repeat chlamydia detection after treatment is common, and there is concern that treatment failure may be a cause.
Methods: Within a randomized trial, we established a prospective cohort of 600 participants with anogenital chlamydia diagnoses (200 each of women, heterosexual men, and men who have sex with men [MSM]). Participants were invited for repeat testing at 3 months and to complete a behavioral survey at 4 months.
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Ann Intern Med
November 2016
From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck & Co., Kenilworth, New Jersey.
Background: Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID).
Objective: To evaluate elbasvir-grazoprevir in treating HCV infection in PWID.
Design: Randomized, placebo-controlled, double-blind trial.
Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males.
Sex Transm Dis
November 2013
From the Kirby Institute, University of New South Wales, Sydney, Australia.
Background: The National Human Papillomavirus (HPV) Vaccination Program for females delivering the quadrivalent vaccine Gardasil has been included in the National Immunisation Program in Australia since 2007. Sentinel surveillance data show that genital wart incidence has been steadily declining since then. The objective of this study was to estimate the additional impact on genital warts as a result of male vaccination, which was approved by the Australian government in 2012 and commenced in 2013.
View Article and Find Full Text PDF